Concurrent chemoradiotherapy with weekly carboplatin and paclitaxel may be a feasible option in inoperable stage III non-small cell lung cancer: a single center experience


Calikusu Z. , Sedef A. M. , Saltaoglu P.

CUKUROVA MEDICAL JOURNAL, vol.44, no.1, pp.195-199, 2019 (Journal Indexed in ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 44 Issue: 1
  • Publication Date: 2019
  • Doi Number: 10.17826/cumj.466219
  • Title of Journal : CUKUROVA MEDICAL JOURNAL
  • Page Numbers: pp.195-199

Abstract

Purpose: Concurrent chemoradiotherapy (CCRT) is a standard treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC). An optimal chemotherapy regimen with concurrent thoracic radiotherapy is not known. In this study, we investigated the efficacy and toxicity of CCRT with carboplatin [area under curve (AUC) 2] and paclitaxel (80 mg/m(2)) during CCRT.